公开(公告)号：US20240238425A1

公开(公告)日：2024-07-18

申请号：US18541015

申请日：2023-12-15

Applicant: Pfizer Inc.

Inventor： Jan Antoinette Cusi Romero Adams ,  Yotam Ashkenazi ,  Matthew Frank Brown ,  Jason Kenneth Dutra ,  Michelle Renee Garnsey ,  Xinjun Hou ,  Jisun Lee ,  Yajing Lian ,  Deane Milford Nason, II ,  Steven Victor O'Neil ,  Amanda Brooke Pecora ,  Alistair Dean Richardson ,  Matthew Forrest Sammons ,  Yang Wang ,  Ann Sorrentino Wright ,  Jun Xiao ,  Lei Zhang ,  Liying Zhang

IPC: A61K47/55 ,  A61K45/06

CPC classification number: A61K47/55 ,  A61K45/06

Abstract: Described herein are 3-fluoro-4-hydroxybenzamide-containing inhibitors and/or degraders, and pharmaceutical compositions containing 3-fluoro-hydroxybenzamide-containing inhibitors and/or degraders. In some embodiments, the 3-fluoro-4-hydroxybenzamide-containing compounds of the disclosure can be used to treat a condition, for example, nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.

公开(公告)号：US11905284B2

公开(公告)日：2024-02-20

申请号：US17335666

申请日：2021-06-01

Applicant: PFIZER INC.

Inventor： Lei Zhang ,  Christopher Ryan Butler ,  Elizabeth Mary Beck ,  Michael Aaron Brodney ,  Matthew Frank Brown ,  Laura Ann McAllister ,  Erik Alphie LaChapelle ,  Adam Matthew Gilbert

IPC: C07D471/04 ,  A61P25/00 ,  A61P25/16 ,  A61P25/18 ,  A61P25/28 ,  A61K31/437

CPC classification number: C07D471/04 ,  A61K31/437 ,  A61P25/00 ,  A61P25/16 ,  A61P25/18 ,  A61P25/28

Abstract: The present invention provides, in part, compounds of Formula I:




or an N-oxide thereof, or a pharmaceutically acceptable salt of the compound or the N-oxide, wherein: R1, R2, L, A, and E are as described herein; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds, N-oxides, or salts, and their uses for treating M4-mediated (or M4-associated) disorders including, e.g., Alzheimer's Disease, schizophrenia (e.g., its cognitive and negative symptoms), pain, addiction, and a sleep disorder.

公开(公告)号：US11339159B2

公开(公告)日：2022-05-24

申请号：US16926933

申请日：2020-07-13

Applicant: Pfizer Inc.

Inventor： Omar Ahmad ,  Andrew Fensome ,  Erik Alphie LaChapelle ,  Ethan Lawrence Fisher ,  Rayomand J. Unwalla ,  Jun Xiao ,  Lei Zhang

IPC: C07D471/04 ,  A61K31/437

Abstract: The present invention relates to imidazo-pyridinyl compounds, or a pharmaceutically acceptable salt thereof, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer, in a subject.

公开(公告)号：US10421744B2

公开(公告)日：2019-09-24

申请号：US16123072

申请日：2018-09-06

Applicant: PFIZER INC.

Inventor： Michael Aaron Brodney ,  Jennifer Elizabeth Davoren ,  Amy Beth Dounay ,  Ivan Viktorovich Efremov ,  David Lawrence Firman Gray ,  Michael Eric Green ,  Jaclyn Louise Henderson ,  Chewah Lee ,  Scot Richard Mente ,  Steven Victor O'Neil ,  Bruce Nelsen Rogers ,  Lei Zhang

IPC: C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D405/14 ,  A61K31/444 ,  A61K31/606 ,  A61K31/513 ,  A61K31/501 ,  A61P25/18 ,  A61P25/28 ,  A61K31/506

Abstract: The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D1-mediated (or D1-associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD, PD, or pharmacotherapy therapy), and Parkinson's disease.

公开(公告)号：US10028962B2

公开(公告)日：2018-07-24

申请号：US15629215

申请日：2017-06-21

Applicant: Pfizer Inc.

Inventor： Michael Aaron Brodney ,  Elizabeth Mary Beck ,  Christopher Ryan Butler ,  Lei Zhang ,  Brian Thomas O'Neill ,  Gabriela Barreiro ,  Erik Alphie LaChapelle ,  Bruce Nelsen Rogers

IPC: C07D519/00 ,  C07D513/04 ,  A61K31/542

CPC classification number: C07D513/04 ,  A61K31/542 ,  C07D519/00

Abstract: The present invention is directed to compounds, tautomers and pharmaceutically acceptable salts of the compounds which are disclosed, wherein the compounds have the structure of Formula I, and the variable R1 is as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

公开(公告)号：US20170369506A1

公开(公告)日：2017-12-28

申请号：US15678511

申请日：2017-08-16

Applicant: Pfizer Inc.

Inventor： Michael Aaron Brodney ,  Christopher Ryan Butler ,  Lei Zhang ,  Brian Thomas O'Neill

IPC: C07D498/04 ,  C07D498/10

CPC classification number: C07D498/04 ,  C07D498/10

Abstract: The present invention is directed to compounds, tautomers and pharmaceutically acceptable salts of the compounds which are disclosed, wherein the compounds have the structure of Formula I, wherein the variables R1, R2, R3, R4 and X are as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

公开(公告)号：US09744173B2

公开(公告)日：2017-08-29

申请号：US15427350

申请日：2017-02-08

Applicant: Pfizer Inc.

Inventor： Michael Aaron Brodney ,  Elizabeth Mary Beck ,  Christopher Ryan Butler ,  Lei Zhang ,  Brian Thomas O'Neill ,  Gabriela Barreiro ,  Erik Alphie LaChapelle ,  Bruce Nelsen Rogers

IPC: C07D519/00 ,  C07D513/04 ,  A61K31/542

CPC classification number: A61K31/542 ,  C07D513/04 ,  C07D519/00

Abstract: The present invention is directed to compounds, tautomers and pharmaceutically acceptable salts of the compounds which are disclosed, wherein the compounds have the structure of Formula I, and the variable R1 is as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

公开(公告)号：US20170088558A1

公开(公告)日：2017-03-30

申请号：US15272501

申请日：2016-09-22

Applicant: Pfizer Inc.

Inventor： Michael Aaron Brodney ,  Christopher Ryan Butler ,  Lei Zhang ,  Brian Thomas O'Neill ,  Patrick Robert Verhoest ,  Peter Justin Mikochik ,  John Charles Murray ,  Xinjun Hou

IPC: C07D513/04 ,  C07D513/20 ,  C07D513/10

CPC classification number: C07D513/04 ,  C07D513/10 ,  C07D513/20

Abstract: The present invention is directed to compounds, tautomers and pharmaceutically acceptable salts of the compounds which are disclosed, wherein the compounds have the structure of Formula I, and the variables R1, R2 and R3 are as defined in the specification.Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

公开(公告)号：US20170088556A1

公开(公告)日：2017-03-30

申请号：US15272651

申请日：2016-09-22

Applicant: Pfizer Inc.

Inventor： Michael Aaron Brodney ,  Christopher Ryan Butler ,  Lei Zhang ,  Brian Thomas O'Neill

IPC: C07D498/04 ,  C07D498/10

CPC classification number: C07D498/04 ,  C07D498/10

Abstract: The present invention is directed to compounds, tautomers and pharmaceutically acceptable salts of the compounds which are disclosed, wherein the compounds have the structure of Formula I, wherein the variables R1, R2, R3, R4 and X are as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

公开(公告)号：US20170008911A1

公开(公告)日：2017-01-12

申请号：US15215193

申请日：2016-07-20

Applicant: Pfizer Inc.

Inventor： Michael Aaron Brodney ,  Elizabeth Mary Beck ,  Christopher Ryan Butler ,  Lei Zhang ,  Brian Thomas O'Neill ,  Gabriela Barreiro ,  Erik Alphie LaChapelle ,  Bruce Nelsen Rogers

IPC: C07D513/04 ,  C07D519/00

CPC classification number: A61K31/542 ,  C07D513/04 ,  C07D519/00

Abstract: The present invention is directed to compounds, tautomers and pharmaceutically acceptable salts of the compounds which are disclosed, wherein the compounds have the structure of Formula I, and the variable R1 is as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

Abstract translation: 并且变量R1如说明书中所定义。 还公开了相应的药物组合物，治疗方法，合成方法和中间体。